SBI-797812

Catalog No.S8980 Batch:S898001

Print

Technical Data

Formula

C19H22N4O4S
Molecular Weight 402.47 CAS No. 2237268-08-3
Solubility (25°C)* In vitro DMSO 80 mg/mL (198.77 mM)
Ethanol 2.5 mg/mL (6.21 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description SBI-797812 is a NAMPT activator which is structurally similar to active-site directed NAMPT inhibitors and blocks binding of these inhibitors to NAMPT. SBI-797812 turns NAMPT into a "super catalyst" that more efficiently generates nicotinamide mononucleotide.
Targets
NAMPT [1]
In vitro

SBI-797812 shifts the NAMPT reaction equilibrium towards nicotinamide mononucleotide formation, increases NAMPT affinity for ATP, stabilizes phosphorylated NAMPT at His247, promotes consumption of the pyrophosphate by-product, and blunts feedback inhibition by NAD+. Treatment of cultured cells with SBI-797812 increases intracellular nicotinamide mononucleotide and NAD+.[1]
In vivo

Plasma concentrations of SBI-797812 after oral administration are low. Higher plasma levels of SBI-797812 are seen after i.p. dosing. The potency of SBI-797812 against mouse NAMPT is investigated. The apparent affinity (EC50) of SBI-797812 for mouse NAMPT is approximately 8-fold less than for human NAMPT, whereas maximal fold activation by SBI-797812 is comparable between the mouse and human NAMPT. Dosing of mice with SBI-797812 elevates liver NAD+.[1]

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    Human A549 lung carcinoma cells

  • Concentrations

    10 μM

  • Incubation Time

    4 h

  • Method

    Human A549 lung carcinoma cells are grown in DMEM, 4.5 g l−1 D-(+)-glucose, 10% fetal bovine serum, penicillin/streptomycin mixture; 10 cm dishes and treated with DMSO (vehicle control) or SBI-797812 for 4 h.
Animal Study:

[1]
  • Animal Models

    8-week-old male C57BL/6 J mice

  • Dosages

    10 mg/kg, 20 mg/kg

  • Administration

    Oral gavage, IP

Selleck's SBI-797812 has been cited by 1 publication

Use of single analytic tool to quantify both absolute N-glycosylation and glycan distribution in monoclonal antibodies [ Biotechnol Prog, 2023, e3365.] PubMed: 37221987

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.